TROPION-Lung01 Study Design and Baseline demographics
PFS by Histology
100
80
Non-squamous
(with and without AGAs)
Median (95% CI),
months
HR
Dato-DXd
100
Docetaxel
5.6 (4.4-7.0) 3.7 (2.9-4.2)
80-
PFS probability, %
50
T
40
20
+ Censored
0.63 (0.51-0.78)
ORR, %
31.2
12.8
DOR, months
7.7
5.6
PFS probability, %
10
20
+ Censored
Daiichi-Sankyo
Squamous
(with and without AGAs)
Median (95% CI),
months
HR
Dato-DXd
Docetaxel
2.8 (1.9-4.0) 3.9 (2.8-4.5)
1.38 (0.94-2.02)
ORR, %
9.2
12.7
DOR, months
5.9
8.1
0
2
6
0
8
10
12
14
16
18
0
2
6
8
10
12
14
16
18
Time since randomization, months
Time since randomization, months
No. at risk
Dato-DXd 229
178
134
86
68
41
20
Docetaxel 232
135
90
50
32
14
10
No. at risk
0
Dato-DXd 70
38
22
10
0 0
Docetaxel 73
51
30
13
03
65
4
3
1
0
10
5
3
PFS HR for non-squamous without AGAs: 0.71 (0.56, 0.91)
AGA, actionable genomic alteration; DOR, duration of response; HR, hazard ratio; ORR, objective response ratel PFS, progression-free survival.
Squamous subset included 3 patients with AGAS
11View entire presentation